SCHEMBL10207078

SCHEMBL10207078

CC1(C)C(=O)Nc2cccc(CNc3nc(Nc4ccc(C5CCCN(CCO)C5)cc4)ncc3Br)c21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STAT6 P42226 1/20 0.40
▸ TNK2 Q07912 5/20 0.39
▸ CDK1 P06493 1/20 0.39
▸ PTK2 Q05397 4/20 0.39
▸ PTK2B Q14289 1/20 0.37
▸ TBK1 Q9UHD2 4/20 0.37
▸ IGF1R P08069 1/20 0.37
▸ MAP4K1 Q92918 1/20 0.37
▸ AURKA O14965 1/20 0.36
▸ AURKB Q96GD4 1/20 0.36
▸ AXL P30530 1/20 0.36
▸ TYRO3 Q06418 1/20 0.36
▸ MERTK Q12866 1/20 0.36
▸ SYK P43405 1/20 0.35
▸ NUAK1 O60285 1/20 0.35
▸ STK16 O75716 1/20 0.35
▸ NTRK1 P04629 1/20 0.35
▸ CSNK2A2 P19784 1/20 0.35
▸ TYK2 P29597 1/20 0.35
▸ BMPR2 Q13873 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10205202 0.92 JAK3 (0.40) STAT6TNK2PTK2NTRK1
SCHEMBL10206634 0.92 STAT6 (0.44) STAT6TNK2CDK1PTK2PTK2B
SCHEMBL10205927 0.92 TNK2 (0.39) STAT6TNK2CDK1PTK2PTK2B
SCHEMBL10205193 0.90 TNK2 (0.39) TNK2CDK1PTK2TBK1IGF1R
SCHEMBL10205925 0.90 IGF1R (0.39) STAT6TNK2CDK1PTK2PTK2B
SCHEMBL10207058 0.89 TNK2 (0.47) TNK2IGF1R
SCHEMBL10206207 0.88 PTK2 (0.40) STAT6TNK2CDK1PTK2PTK2B
SCHEMBL10207024 0.85 TNK2 (0.46) TNK2CDK1PTK2PTK2BIGF1R
SCHEMBL10206198 0.84 STAT6 (0.42) STAT6TNK2CDK1PTK2PTK2B
SCHEMBL10206633 0.84 EGFR (0.46) STAT6TNK2MAP4K1AXLTYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655358-B1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2014-11-19 — — EP disclosed
US-8546443-B2 Benzylic oxindole pyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 — — US disclosed
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-27 — — US disclosed
WO-2012085126-A1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES MKI67, CCNI, CCNB1 STAT6 1155/4885TNK2 646/4885CDK1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback